Tamsulosin: Drug information

Official reprint from UpToDate® www.uptodate.com

©2021 UpToDate®

Tamsulosin: Drug information

Copyright 1978-2021 Lexicomp, Inc. All rights reserved.

(For additional information see "Tamsulosin: Patient drug information" and see "Tamsulosin: Pediatric drug
information")

For abbreviations and symbols that may be used in Lexicomp (show table)

Brand Names: US
Flomax

Brand Names: Canada

APO-Tamsulosin CR; Flomax CR; RATIO-Tamsulosin [DSC]; SANDOZ Tamsulosin; SANDOZ
Tamsulosin CR; TEVA-Tamsulosin CR; TEVA-Tamsulosin [DSC]

Pharmacologic Category
Alpha 1 Blocker

Dosing: Adult
Note: Tamsulosin capsules should be administered ~30 minutes following the same meal each
day. The controlled-release (oral controlled absorption system [OCAS]) tablet formulation
[Canadian product] should be administered at the same time each day with or without food.

Benign prostatic hyperplasia: Oral:

Capsule: Initial and maintenance: 0.4 mg once daily. If response is inadequate after 2
to 4 weeks, may increase to 0.8 mg once daily. If therapy is discontinued or interrupted
for several days, restart with 0.4 mg once daily.

Controlled-release tablet [Canadian product]: Initial and maximum dose: 0.4 mg once
daily.

Chronic prostatitis/chronic pelvic pain syndrome in males (off-label use): Oral: Initial:

- Page 1 of 21 -
Tamsulosin: Drug information

0.4 mg once daily for 6 weeks as part of an appropriate combination regimen (Pontari 2020;
Thakkinstian 2012). If response to initial therapy is inadequate, referral to a urologist is
recommended (Anothaisintawee 2011; Nickel 2012; Pontari 2020).

Lower urinary tract symptoms in males (off-label use): Bladder outlet obstruction and
low postvoid residual: Oral: Initial: 0.4 mg once daily; may combine with an anticholinergic
agent if symptoms of overactive bladder persist (Athanasopoulos 2003; Dimitropoulos 2015;
Drake 2015; Van Kerrebroeck 2013).

Ureteral calculi expulsion (off-label use):

Medical expulsive therapy for distal (lower) ureteral calculi to facilitate spontaneous
stone passage: Stones >5 and ≤10 mm: Oral: 0.4 mg once daily until stone passage
occurs or for up to 4 weeks (Ahmed 2010; Campschroer 2014; Hollingsworth 2016; Ye
2017).

Adjunctive therapy following shock wave lithotripsy to facilitate clearance of residual

stones: Oral: 0.4 mg once daily; initiate therapy immediately after extracorporeal shock
wave lithotripsy; duration of therapy in trials ranged from 14 days to 3 months (Agrawal
2009; Chen 2015; Falahatkar 2011; Vicentini 2011).

Ureteral stent-related urinary symptoms, treatment (off-label use): Oral: 0.4 mg once
daily; treatment was initiated following stent placement and duration of therapy in trials
ranged from 1 to 6 weeks (Damiano 2008; Wang 2009a; Wang 2009b; Yakoubi 2011); may
also be given in combination with an anticholinergic agent (Dellis 2017).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring
dose/frequency adjustment or avoidance. Consult drug interactions database for more
information.

Dosing: Renal Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical
expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts,
PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥10 mL/minute: No dosage adjustment necessary (Koiso 1996; Miyazawa 2001;
- Page 2 of 21 -
Tamsulosin: Drug information

Wolzt 1998; manufacturer’s labeling).

CrCl <10 mL/minute: No dosage adjustment likely to be necessary (has not been
studied); use with caution (expert opinion).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (highly protein bound):

No dosage adjustment likely to be necessary (has not been studied); use with caution
(expert opinion).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): No dosage adjustment

likely to be necessary (has not been studied); use with caution (expert opinion).

Dosing: Hepatic Impairment: Adult

Mild-to-moderate impairment: No dosage adjustment is necessary.

Severe impairment: There are no dosage adjustments provided in the manufacturer’s

labeling (has not been studied).

Dosing: Pediatric

(For additional information see "Tamsulosin: Pediatric drug information")

Nephrolithiasis, distal stones: Limited data available; optimal dose not established
(Mokhless 2012; Tasian 2014):

Children 2 to 4 years: Oral: 0.2 or 0.4 mg once daily at bedtime

Children >4 years and Adolescents: Oral: 0.4 mg once daily at bedtime

Dosing based on two studies. The larger was a multi-institutional retrospective

cohort study of pediatric patients with stones up to 10 mm; patients received either
tamsulosin 0.4 mg once daily (n=99, median age: 14.8 years) or analgesics alone
(n=175). Spontaneous stone passage was higher in the treatment group (55% vs
44%, p=0.03); treatment group was older and had smaller, more distal stones.
When adjusted for stone size and location as part of analysis of 99 case matched
pairs, success was also higher in the treatment group (OR 3.31, 95% CI: 1.49 to
7.34) (Tasian 2014). The smaller study was a prospective, randomized controlled
trial of pediatric patients with stones up to 12 mm; patients received either
tamsulosin 0.4 mg once daily (0.2 mg if ≤4 years old) (n=33, age: 2 to 15 years) or
- Page 3 of 21 -
Tamsulosin: Drug information

placebo (n=28). In this study, 45% of the treatment group had previously received
either extracorporeal shock wave lithotripsy (ESWL) or percutaneous
nephrolithotomy, but none in the control group had received these therapies;
however, stone size at the start of treatment was similar between groups.
Treatment resulted in higher expulsion rate (87.8% vs 64.2%, p<0.01), less days to
expulsion (mean: 8.2 vs 14.5 days, p<0.001), less pain episodes (mean: 1.4 vs
2.2, p<0.02) and less need for analgesia (mean: 0.7 vs 1.4, p<0.02) (Mokhless
2012). In both studies, tamsulosin was well tolerated and there were no reported
adverse effects.

Primary bladder neck dysfunction: Limited data available: Children ≥3 years and
Adolescents: Oral: Initial dose: 0.2 mg once daily, increase by 0.2 mg increments based
on response (symptoms and urodynamic studies) and tolerability. Mean effective dose:
0.4 mg daily; maximum reported daily dose: 0.8 mg/day. Dosing based on two trials
evaluating treatment with alpha blockers, including over 50 pediatric patients who
received tamsulosin. Treatment resulted in improved urine flow rates and decreased
post-void residual urine volume; values returned to pretreatment levels when therapy
was discontinued. Tamsulosin was well tolerated with no major adverse effects and
benefits continued for at least 3 years (Donohoe 2005; Van Batavia 2010).

Dosing: Renal Impairment: Pediatric

There are no pediatric-specific recommendations. Based on experience in adult male patients
with CrCl ≥10 mL/minute, data suggest no adjustment needed; for more severe renal
impairment, use has not been studied.

Dosing: Hepatic Impairment: Pediatric

There are no pediatric-specific recommendations. Based on experience in adult male patients
with mild to moderate hepatic impairment, data suggest no adjustment needed; for more severe
hepatic impairment, use has not been studied.

Dosing: Geriatric
Refer to adult dosing.

Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult
specific product labeling.

- Page 4 of 21 -
Tamsulosin: Drug information

Capsule, Oral, as hydrochloride:

Flomax: 0.4 mg [contains fd&c blue #2 (indigotine)]

Generic: 0.4 mg

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult
specific product labeling.

Capsule Extended Release 24 Hour, Oral:

Generic: 0.4 mg

Tablet Extended Release 24 Hour, Oral:

Flomax CR: 0.4 mg

Generic: 0.4 mg

Administration: Adult
Oral: Administer capsules 30 minutes after the same mealtime each day. Capsules should be
swallowed whole; do not crush, chew, or open. The controlled-release tablet [Canadian product]
should be administered at the same time each day with or without food, and should be
swallowed whole.

Administration: Pediatric
Oral: Per the manufacturer, capsules should be swallowed whole; do not crush, chew, or open.
In pediatric trials, capsules were opened and the contents mixed with food (eg, yogurt or
pudding) or juice (Donohoe 2005; Tasian 2014).

Use: Labeled Indications

Benign prostatic hyperplasia: Treatment of signs and symptoms of benign prostatic

hyperplasia (BPH)

Limitations of use: Not indicated for the treatment of hypertension.

- Page 5 of 21 -
Tamsulosin: Drug information

Use: Off-Label: Adult

Chronic prostatitis/chronic pelvic pain syndrome in males; Lower urinary tract symptoms in
males; Ureteral calculi expulsion; Ureteral stent-related urinary symptoms, treatment

Medication Safety Issues

Sound-alike/look-alike issues:

Flomax may be confused with Flonase, Flovent, Foltx, Fosamax

Tamsulosin may be confused with tacrolimus, tamoxifen, terazosin

International issues:

Flomax [US, Canada, and multiple international markets] may be confused with Flomox
brand name for cefcapene [Japan]; Volmax brand name for salbutamol [multiple
international markets]

Flomax: Brand name for tamsulosin [US, Canada, and multiple international markets],
but also the brand name for morniflumate [Italy]

Adverse Reactions (Significant): Considerations

Floppy iris syndrome

Intraoperative floppy iris syndrome has been reported in patients with current or prior use
of alpha-1 blockers, particularly tamsulosin, undergoing cataract or glaucoma surgery (Ref).

Mechanism: Unclear; may be related to a combination of the pharmacologic action (ie,

inhibition of the iris dilator smooth muscle contraction) and long-term smooth muscle
atrophy from accumulation in iris pigment epithelial cells (Ref).

Onset: Varied; may occur with current (within a few weeks of initiation) or prior use
(years following discontinuation) (Ref).

Risk factors:

• Individual alpha-1 blocker (particularly tamsulosin) (Ref).

• Hypertension may be an independent risk factor (Ref).

- Page 6 of 21 -
Tamsulosin: Drug information

Orthostatic hypotension

Use may cause orthostatic hypotension, dizziness, and vertigo.

Mechanism: Dose-related; related to the pharmacologic action (ie, inhibition of vascular

smooth muscle contraction) (Ref).

Onset: Rapid; “first dose” orthostatic hypotension may occur 4 to 8 hours after dose.

Risk factors:

• Individual alpha-1 blocker (tamsulosin among lowest risk) (Ref)

• First dose or restart after dose interruption (Ref)

• Rapid increase in dose

• Concomitant antihypertensives (especially vasodilators) (Ref)

• Concomitant phosphodiesterase-5 inhibitors (eg, sildenafil)

• Alcohol use (Ref)

Adverse Reactions
The following adverse drug reactions and incidences are derived from product labeling unless
otherwise specified.

>10%:

Cardiovascular: Orthostatic hypotension (by orthostatic testing: first dose: 6% to 7%

[placebo: 3% to 4%], chronic use: 16% to 19% [placebo: 11%]; symptomatic: <1%
[placebo: 0%])

Genitourinary: Ejaculation failure (8% to 18%)

Infection: Infection (9% to 11%)

Nervous system: Dizziness (15% to 17% [placebo: 10%]), headache (19% to 21%)

Respiratory: Rhinitis (13% to 18%)

1% to 10%:
- Page 7 of 21 -
Tamsulosin: Drug information

Endocrine & metabolic: Decreased libido (2%)

Gastrointestinal: Diarrhea (6%), nausea (4%)

Nervous system: Drowsiness (3% to 4%), insomnia (1% to 2%), vertigo (1% [placebo:
0.6%])

Neuromuscular & skeletal: Asthenia (8% to 9%), back pain (7% to 8%)

Ophthalmic: Blurred vision (≤2%)

Respiratory: Increased cough (3% to 5%), pharyngitis (6%), sinusitis (4%)

Postmarketing:

Cardiovascular: Atrial fibrillation, tachycardia

Dermatologic: Contact dermatitis (Lijnen 2003), erythema multiforme (Hu 2019),

exfoliative dermatitis, skin photosensitivity (Tan 2018), Stevens-Johnson syndrome

Gastrointestinal: Constipation, vomiting, xerostomia

Genitourinary: Priapism (Marconi 2019)

Hypersensitivity: Angioedema, fixed drug eruption (Montazer 2020)

Ophthalmic: Choroidal detachment (Kerimoglu 2010), intraoperative floppy iris

syndrome (in patients undergoing cataract or glaucoma surgery) (Keklikci 2009)

Respiratory: Dyspnea, epistaxis

Contraindications

Hypersensitivity (eg, angioedema, rash, urticaria, pruritus, respiratory symptoms) to

tamsulosin or any component of the formulation
Canadian labeling: Additional contraindications (not in US labeling): Concomitant use with
strong CYP3A4 inhibitors (including ketoconazole)

Warnings/Precautions

Concerns related to adverse effects:

• Angina: Discontinue if symptoms of angina occur or worsen.

- Page 8 of 21 -
Tamsulosin: Drug information

• Sulfonamide allergy: Rarely, patients with a sulfa allergy have also developed an
allergic reaction to tamsulosin; avoid use when previous reaction has been severe or
life-threatening.

Disease-related concerns:

• Heart failure: In a scientific statement from the American Heart Association,

tamsulosin has been determined to be an agent that may exacerbate underlying
myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).

Warnings: Additional Pediatric Considerations

Tamsulosin has been well tolerated in pediatric patients during trials when used for management
of nephrolithiasis and primary bladder neck dysfunction (Donohoe 2005; Mokhless 2012; Tasian
2014; Van Batavia 2010). Studies using tamsulosin for the management of elevated detrusor
leak point pressure in pediatric patients (ages 2 to 16 years) with a known neurological disorder
(eg, spina bifida) failed to show efficacy.

Metabolism/Transport Effects
Substrate of CYP2D6 (major), CYP3A4 (major); Note: Assignment of Major/Minor substrate
status based on clinically relevant drug interaction potential

Drug Interactions
(For additional information: Launch drug interactions program)

Abametapir: May increase the serum concentration of CYP3A4 Substrates (High risk with
Inhibitors). Risk X: Avoid combination

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with
Inhibitors). Risk C: Monitor therapy

Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-

/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker
vasodilation. Risk C: Monitor therapy

Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-

Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Risk C:
Monitor therapy

Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers. Risk X:

- Page 9 of 21 -
Tamsulosin: Drug information

Avoid combination

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of
Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering
medications for 24 hours before amifostine administration. If blood pressure lowering
therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses
of amifostine. Risk D: Consider therapy modification

Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.

Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may
enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).
Risk C: Monitor therapy

Artemether and Lumefantrine: May increase the serum concentration of CYP2D6

Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk
C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk
C: Monitor therapy

Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk
associated with ophthalmic products is probably less than systemic products. Risk C:
Monitor therapy

Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-
Associated Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering
Agents. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents.
Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk
X: Avoid combination

Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of

Calcium Channel Blockers. Risk C: Monitor therapy
- Page 10 of 21 -
Tamsulosin: Drug information

Cimetidine: May increase the serum concentration of Tamsulosin. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with
Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin. Risk
C: Monitor therapy

CYP2D6 Inhibitors (Strong): May increase the serum concentration of Tamsulosin. Risk C:
Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin. Risk
C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tamsulosin. Risk X:
Avoid combination

Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. Risk C:

Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C:
Monitor therapy

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of
DULoxetine. Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with
Inhibitors). Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with
Inhibitors). Risk X: Avoid combination

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates
(High risk with Inhibitors). Risk X: Avoid combination

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect
of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the

hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

- Page 11 of 21 -
Tamsulosin: Drug information

Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the

hypotensive effect of Levodopa-Containing Products. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk
C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C:
Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of
Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Management: Consider temporarily withholding blood pressure lowering medications
beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end
of the infusion. Risk D: Consider therapy modification

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High
risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of
CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of
Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure

Lowering Agents. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: Alpha1-Blockers (Uroselective) may enhance the

hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering
Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk

- Page 12 of 21 -
Tamsulosin: Drug information

C: Monitor therapy

Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. Risk C:

Monitor therapy

Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with
Inhibitors). Risk C: Monitor therapy

Food Interactions
Capsules: Fasting increases bioavailability by 30% and peak concentration 40% to 70%.
Management: Administer 30 minutes after the same meal each day. Note: The controlled-
release tablet formulation [Canadian product] is not affected by food and can be taken with or
without food at the same time each day.

Reproductive Considerations
Ejaculation failure, ejaculation disorder, retrograde ejaculation, and decreased ejaculation has
been associated with use of tamsulosin.

Pregnancy Considerations
Information related to the use of tamsulosin for ureteral calculi expulsion in pregnancy is limited
(Bailey 2016; Theriault 2020). Other treatments such as stents or ureteroscopy, are currently
recommended if stone removal is needed (AUA/ES [Assimos 2016]; EAU [Türk 2019]; Lloyd
2016).

Breast-Feeding Considerations
It is not known if tamsulosin is present in breast milk.

Monitoring Parameters
Blood pressure; urinary symptoms; prostate cancer screening prior to initiation and then as
directed; mental alertness.

Mechanism of Action
Tamsulosin is an antagonist of alpha1A-adrenoreceptors in the prostate. Smooth muscle tone in
the prostate is mediated by alpha1A-adrenoreceptors; blocking them leads to relaxation of
smooth muscle in the bladder neck and prostate causing an improvement of urine flow and
decreased symptoms of BPH. Approximately 75% of the alpha1-receptors in the prostate are of
the alpha1A subtype.
- Page 13 of 21 -
Tamsulosin: Drug information

Pharmacodynamics and Pharmacokinetics

Note: Pharmacokinetics in pediatric patients (ages 2 to 16 years) were found to be similar

to adult values (Tsuda 2010).

Absorption: >90%

Distribution: Vd: 16 L

Protein binding: 94% to 99%, primarily to alpha-1 acid glycoprotein (AAG)

Metabolism: Hepatic (extensive) via CYP3A4 and 2D6; metabolites undergo extensive
conjugation to glucuronide or sulfate

Bioavailability: Fasting: 30% increase

Steady-state: By the fifth day of once-daily dosing

Half-life elimination: Healthy volunteers: 9 to 13 hours; Target population: 14 to 15 hours

Time to peak: Fasting: 4 to 5 hours; With food: 6 to 7 hours

Excretion: Urine (76%, <10% as unchanged drug); feces (21%)

Pharmacodynamics and Pharmacokinetics: Additional Considerations

Geriatric: AUC is 40% higher in subjects 55 to 75 years of age compared with subjects 20 to
32 years of age.

Pricing: US

Capsules (Flomax Oral)

0.4 mg (per each): $10.62

Capsules (Tamsulosin HCl Oral)

0.4 mg (per each): $4.20 - $4.22

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided
as reference price only. A range is provided when more than one manufacturer's AWP price is
available and uses the low and high price reported by the manufacturers to determine the range.

- Page 14 of 21 -
Tamsulosin: Drug information

The pricing data should be used for benchmarking purposes only, and as such should not be
used alone to set or adjudicate any prices for reimbursement or purchasing functions or
considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly
disclaims all warranties of any kind or nature, whether express or implied, and assumes no
liability with respect to accuracy of price or price range data published in its solutions. In no
event shall Medi-Span be liable for special, indirect, incidental, or consequential damages
arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International

Adenorm (UA); Alna (AT, DE); Bazetham (HR); Bestflo (LK); Comadex (EC); Contiflo OD (QA,
ZW); Curepro XR (EG); Expros (FI); Eziflo (BD); Flectone XL (GB); Flomax (BB, TR, ZA);
Flomaxtra (AU); Flomaxtra XL (GB); Flosin (LV, UA); Flosure (LK); Fokusin (LV, RO); Gotam (IN);
Harnal (CN, HK, ID, JP, MY, SG, TH); Harnal D (PH); Harnal OCAS (PH, VN); Harnalidge D
(TW); Harusin SR (KR); Inreq (ES); Josir (FR); Kirnom (IE); Libert (CR, DO, GT, HN, NI, PA,
SV); Losiprost (EG); Lostam (EC); Lutsnal (KR); Maxflow (LK); Maxrin (LK); Mecir (FR); Mingo
(LB); Omexel (FR); Omic (BE, LU); Omix Ocas (CH); Omnexel (IE); Omnic (AE, AR, BH, BR,
CL, CO, CZ, DE, DK, EE, EG, ES, FI, GR, HR, HU, IL, IS, IT, JO, KW, LT, MT, NL, NO, PE, PL,
PT, QA, RO, RU, SA, SI, SK, UA); Omnic OCAS (CY, EG, KW, LB, QA, SA); Omnic Tocas (BG);
Omnistad (DK); Omsal (LV, ZA); Palnac (JP); Petyme (GB); Pimax (PH); Pinexel PR (MT);
Promnix (IL); Prosta-Tab PR (BH); Protam (NL); Prozelax (PH); Ranomax (BE); Sasolin (BD);
Sebrane (ES); Secotex (AR, BR, CL, CO, CR, DO, GT, HN, MX, NI, PA, PE, PY, SV, UY, VE);
Secotex OCAS (CR, DO, EC, GT, HN, NI, PA, SV); Sulosin (KR); Sultam (PH); Tabphyn MR
(GB); Talusin (LB); Taluso (NL); Tamic (EG); Tamlosin (TW); Tamlosin SR (KR); Tamnexyl (IE);
Tamnic (IE); Tamodof (VN); Tamsin (LK); Tamsnal SR (KR); Tamsol (BD); Tamsu (IE); Tamsul
(ZA); Tamsulid (UA); Tamsulin (IL, KW); Tamsulo (KR); Tamsulon (CR, DO, EC, GT, HN, NI, PA,
SV); Tamsustad (HK, VN); Tamunal (KR); Tarunal (KR); Urilax (PH); Urimax (IN, PH, VE); Urnal
(TW); Uroflo (BD); Uroflow (TH); Urostad (LV); Urotams SR (KR); Xalgetz (VN); Zotan (TW);
Zuantrip (ES)

For country abbreviations used in Lexicomp (show table)

REFERENCES

1. Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. Curr Opin Ophthalmol.

2009;20(1):37-41. doi:10.1097/ICU.0b013e32831bc0ad [PubMed 19077827]
2. Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P. Prospective randomized
- Page 15 of 21 -
Tamsulosin: Drug information

trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral

stones. Urology. 2009;73(4):706-709. doi:10.1016/j.urology.2008.11.013 [PubMed
19193417]

3. Ahmed AF, Al-Sayed AY. Tamsulosin versus alfuzosin in the treatment of patients with distal
ureteral stones: Prospective, randomized, comparative study. Korean J Urol.
2010;51(3):193-197. doi:10.4111/kju.2010.51.3.193. [PubMed 20414396]

4. Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic

pelvic pain syndrome: a systematic review and network meta-analysis. JAMA.
2011;305(1):78-86. doi:10.1001/jama.2010.1913 [PubMed 21205969]

5. Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American

Urological Association/Endourological Society Guideline, PART I. J Urol. 2016;196(4):1153-
1160. doi:10.1016/j.juro.2016.05.090 [PubMed 27238616]

6. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G.

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet
obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253-2256.
doi:10.1097/01.ju.0000067541.73285.eb [PubMed 12771763]

7. Bailey G, Vaughan L, Rose C, et al. Perinatal outcomes with tamsulosin therapy for
symptomatic urolithiasis. J Urol. 2016;195(1):99-103. doi:10.1016/j.juro.2015.06.097.
[PubMed 26144335]

8. Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical

expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2014;(4):CD008509.
doi:10.1002/14651858.CD008509.pub2 [PubMed 24691989]

9. Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive

therapy for ureteral stones. Cochrane Database Syst Rev. 2018;4:CD008509.
doi:10.1002/14651858.CD008509.pub3 [PubMed 29620795]

10. Chen K, Mi H, Xu G, et al. The efficacy and safety of tamsulosin combined with
extracorporeal shockwave lithotripsy for urolithiasis: A systematic review and meta-analysis
of randomized controlled trials. J Endourol. 2015;29(10):1166-1176.
doi:10.1089/end.2015.0098 [PubMed 25915454]

11. Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-
associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2006;32(8):1336-
1339. doi:10.1016/j.jcrs.2006.03.034 [PubMed 16863971]

- Page 16 of 21 -
Tamsulosin: Drug information

12. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of

tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol.
2008;22(4):651-656. doi:10.1089/end.2007.0257 [PubMed 18338955]

13. Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA.
Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms:
A randomized controlled study. J Endourol. 2017;31(1):100-109. doi:
10.1089/end.2016.0663 [PubMed 27809592]

14. Dimitropoulos K, Gravas S. Solifenacin/tamsulosin fixed-dose combination therapy to treat

lower urinary tract symptoms in patients with benign prostatic hyperplasia. Drug Des Devel
Ther. 2015;9:1707-1716. doi:10.2147/DDDT.S53184 [PubMed 25834406]

15. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-

adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of
benign prostatic obstruction. Eur Urol. 1999;36(1):1-13. doi:10.1159/000019919 [PubMed
10364649]
16. Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and
adolescents II: results of treatment with alpha-adrenergic antagonists. J Urol.
2005;173(1):212-216. doi:10.1097/01.ju.0000135735.49099.8c [PubMed 15592078]

17. Drake MJ, Chapple C, Sokol R, et al; NEPTUNE Study Group. Long-term safety and
efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled
absorption system in men with storage and voiding lower urinary tract symptoms: results
from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol.
2015;67(2):262-270. doi:10.1016/j.eururo.2014.07.013 [PubMed 25070148]
18. Falahatkar S, Khosropanah I, Vajary AD, Bateni ZH, Khosropanah D, Allahkhah A. Is there
a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral
calculi? J Endourol. 2011;25(3):495-498. doi:10.1089/end.2010.0439 [PubMed 21166579]
19. Fan B, Yang D, Wang J, et al. Can tamsulosin facilitate expulsion of ureteral stones? A
meta-analysis of randomized controlled trials. Int J Urol. 2013;20(8):818-830.
doi:10.1111/iju.12048 [PubMed 23278872]
20. Flomax (tamsulosin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC;
January 2019.

21. Flomax CR (tamsulosin) [product monograph]. Burlington, Ontario, Canada: Boehringer

Ingelheim (Canada) Ltd; August 2019.

- Page 17 of 21 -
Tamsulosin: Drug information

22. Furyk JS, Chu K, Banks C, et al. Distal ureteric stones and tamsulosin: A double-blind,
placebo-controlled, randomized, multicenter trial. Ann Emerg Med. 2016;67(1):86-95.e2.
doi:10.1016/j.annemergmed.2015.06.001 [PubMed 26194935]
23. Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric
stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. doi:10.1136/bmj.i6112
[PubMed 27908918]
24. Hu L, Dong J, Zhang S. Tamsulosin-Associated Erythema Multiforme-Like Eruption. Am J
Ther. 2019 Aug 16. doi:10.1097/MJT.0000000000001059 [PubMed 31513023]
25. Keklikci U, Isen K, Unlu K, Celik Y, Karahan M. Incidence, clinical findings and management
of intraoperative floppy iris syndrome associated with tamsulosin. Acta Ophthalmol.
2009;87(3):306-309. doi:10.1111/j.1755-3768.2008.01246.x [PubMed 18384448]
26. Kerimoglu H, Zengin N, Ozturk B, Gunduz K. Unilateral chemosis, acute onset myopia and
choroidal detachment following the use of tamsulosin. Acta Ophthalmol. 2010;88(2):e20-
e21. doi:10.1111/j.1755-3768.2008.01503.x [PubMed 19302075]
27. Koiso K, Akaza H, Kikuchi K, et al. Pharmacokinetics of tamsulosin hydrochloride in
patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol.
1996;36(11):1029-1038. doi:10.1177/009127009603601107 [PubMed 8973992]
28. Lijnen RL, de Graaf L. Systemic contact dermatitis from tamsulosin. Contact Dermatitis.
2003;49(1):50-51. doi:10.1111/j.0105-1873.2003.0120k.x [PubMed 14641131]
29. Lloyd GL, Lim A, Hamoui N, et al. The use of medical expulsive therapy during pregnancy:
a worldwide perspective among experts. J Endourol. 2016;30(3):354-358.
doi:10.1089/end.2015.0587 [PubMed 26482104]
30. Marconi M, Pavez P, San Francisco I, Narvaez P. Priapism induced by use of tamsulosin: A
case report and review of the literature. Arch Ital Urol Androl. 2019;91(3).
doi:10.4081/aiua.2019.3.193 [PubMed 31577106]
31. Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in
subjects with normal and impaired renal or hepatic function. Current Therapeutic Research.
2001;62(9):603-621. doi:10.1016/S0011-393X(01)80067-9
32. Mokhless I, Zahran AR, Youssif M, Fahmy A. Tamsulosin for the management of distal
ureteral stones in children: a prospective randomized study. J Pediatr Urol. 2012;8(5):544-
548. doi:10.1016/j.jpurol.2011.09.008 [PubMed 22099477]
33. Montazer F, Jahani Amiri K, Mofarrah R, Ahmadi A, Nouripour B, Mofarrah R. A first case of
- Page 18 of 21 -
Tamsulosin: Drug information

fixed drug eruption due to tamsulosin. J Cosmet Dermatol. 2020;19(5):1143-1145.

doi:10.1111/jocd.13125 [PubMed 31541583]
34. Nickel JC, Touma N. α-Blockers for the treatment of chronic prostatitis/chronic pelvic pain
syndrome: An update on current clinical evidence. Rev Urol. 2012;14(3-4):56-64. [PubMed
23526487]
35. Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor
antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf.
2014;13(9):1187-1197. doi:10.1517/14740338.2014.936376 [PubMed 25073735]
36. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical
Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical
Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular
and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That
May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart
Association. Circulation. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426
[PubMed 27400984]

37. Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications

employed in treating benign prostatic hyperplasia and food - A short review. Biomed
Pharmacother. 2016;83:1141-1145. doi:10.1016/j.biopha.2016.08.021 [PubMed 27551761]

38. Pontari, M. Chronic prostatitis and chronic pelvic pain syndrome. Post TW, ed. UpToDate.
Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 1, 2020.

39. Preminger GM, Tiselius HG, Assimos DG, et al; EAU/AUA Nephrolithiasis Guideline Panel.
2007 guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418-2434. doi:
10.1016/j.juro.2007.09.107 [PubMed 17993340]

40. Ramsey E, Ramsey BL 3rd, Childers J. Floppy iris syndrome: a drug-related complication of
cataract surgery. JAAPA. 2012;25(5):37-38, 41. doi:10.1097/01720610-201205000-00007
[PubMed 22712147]
41. Schulman C. Hypertrophie bénigne de la prostate: quel traitement, pour qui? [Benign
hypertrophy of the prostate: which treatment, for whom?] [in French]. Rev Med Brux.
1999;20(4):A212-A218. [PubMed 10523895]
42. Tan CK, Yap KB. Tamsulosin-induced photosensitivity rash. Singapore Med J.
2018;59(6):336-337. doi:10.11622/smedj.2018072 [PubMed 29974124]
43. Tan YK, Cha DY, and Gupta M, "Management of Stones in Abnormal Situations," Urol Clin

- Page 19 of 21 -
Tamsulosin: Drug information

North Am, 2013, 40(1):79-97. [PubMed 23177637]

44. Tasian GE, Cost NG, Granberg CF, et al. Tamsulosin and spontaneous passage of ureteral
stones in children: a multi-institutional cohort study. J Urol. 2014;192(2):506-511. [PubMed
24518765]
45. Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-
inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain
syndrome. BJU Int. 2012;110(7):1014‐1022. doi:10.1111/j.1464-410X.2012.11088.x
[PubMed 22471591]
46. Theriault B, Morin F, Cloutier J. Safety and efficacy of Tamsulosin as medical expulsive
therapy in pregnancy. World J Urol. 2020;38(9):2301-2306. doi:10.1007/s00345-019-
03022-z [PubMed 31768615]
47. Tsuda Y, Tatami S, Yamamura N, et al. Population pharmacokinetics of tamsulosin
hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin
Pharmacol. 2010;70(1):88-101. [PubMed 20642551]
48. Van Batavia JP, Combs AJ, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in
children and adolescents III: results of long-term alpha-blocker therapy. J Urol.
2010;183(2):724-730. [PubMed 20022041]
49. Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus
tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results
from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398-407. [PubMed
23537687]
50. Vicentini FC, Mazzucchi E, Brito AH, Chedid Neto EA, Danilovic A, Srougi M. Adjuvant
tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a
double blind, randomized, placebo-controlled trial. Urology. 2011;78(5):1016-1021.
[PubMed 21802124]
51. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary
tract symptoms due to double-J stent: a prospectively randomized study. Urol Res.
2009a;37(3):147-152. [PubMed 19277623]
52. Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms
due to double-J stent: a prospective study. Urol Int. 2009b;83(1):66-69. [PubMed
19641362]
53. Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with

- Page 20 of 21 -
Tamsulosin: Drug information

normal and varying degrees of impaired renal function: an open-label single-dose and
multiple-dose study. Eur J Clin Pharmacol. 1998;54(4):367-373.
doi:10.1007/s002280050477 [PubMed 9696967]
54. Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for α-blockers in
ureteral stent related symptoms? A systematic review and meta-analysis. J Urol.
2011;186(3):928-934. [PubMed 21791359]
55. Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: comparative efficacy
of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with
renal colic. BJU Int. 2011;108(2):276-279. [PubMed 21083640]
56. Ye Z, Zeng G, Yang H, et al. Efficacy and safety of tamsulosin in medical expulsive therapy
for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-
controlled trial [published online November 12, 2017]. Eur Urol. doi:
10.1016/j.eururo.2017.10.033 [PubMed 29137830]

Topic 9654 Version 343.0

© 2021 UpToDate, Inc. All rights reserved.

- Page 21 of 21 -